The latest warning letter to a skin-care manufacturer posted to FDA's website reinforces the agency's stance on product claims that encroach on drug turf and augurs challenges that personal-care firms could face down the road under statutorily imposed good manufacturing practices.
Addressed to Garden Grove, Calif.-based Beauty & Health International Inc., which sells skin-care products and dietary supplements through its website...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?